Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
University of Nebraska
Study ID
NCT01431209
Phase
PHASE2
Status
Completed

Conditions

  • Recurrent Diffuse Large B-Cell Lymphoma
  • Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II trial studies how well ruxolitinib phosphate works in treating patients with diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma that has returned (relapsed) or that does not respond to treatment (refractory) after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date
Aug 12, 2011
Status verified
Sep 2023
Primary completion
Oct 28, 2020
Completion
May 26, 2021

Study Design

Enrollment
71 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (ruxolitinib phosphate)
    Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Overall Response Rate [ Time Frame: 24 weeks ]

Locations (3)

FacilityCityStateZIPSite coordinators
National Institutes of Health Clinical CenterBethesdaMaryland20892-
Mayo ClinicRochesterMinnesota55905-
University of Nebraska Medical CenterOmahaNebraska68198-

Find similar trials in Bethesda, MD

By research site
National Institutes of Health Clinical Center· Bethesda, MDMayo Clinic· Rochester, MNUniversity of Nebraska Medical Center· Omaha, NE

Related Studies